title: Patient Satisfaction and Efficacy of Full-Facial Rejuvenation Using a Combination of Botulinum Toxin Type A and Hyaluronic Acid Filler.
abstract: BACKGROUND
  Combination treatments using hyaluronic acid (HA) fillers and botulinum toxin Type A (BoNT-A) are common in aesthetic medicine; however, this has been evaluated in only a few clinical studies.
  
  
  OBJECTIVE
  To evaluate subject satisfaction, efficacy, and safety of BoNT-A (Speywood Unit; s.U) and a range of HA fillers for full-facial aesthetic rejuvenation.
  
  
  METHODS
  A 6-month, multicenter, open-label clinical study, using BoNT-A (s.U) and 5 HA fillers to treat up to 13 facial zones. Subject satisfaction questionnaires were administered 3 weeks and 6 months after the last injection. Global aesthetic improvement and improvement on each treated zone as well as safety were evaluated.
  
  
  RESULTS
  A high level of satisfaction was achieved throughout the study, with 96.5% of subjects at least satisfied with the full-facial aesthetic outcome at 3 weeks, and 92.9% at 6 months. More than 91% considered the treatment outcome to meet or surpass their expectations, and more than 94% would recommend the treatment to others. At Week 3, subject and investigator assessment showed aesthetic improvement for all subjects. The treatment was well tolerated.
  
  
  CONCLUSIONS
  The combination of BoNT-A (s.U) and HA fillers results in high patient satisfaction and in an overall improvement of aesthetic outcomes and quality of life.
authors.affiliation: *Medikas, Somerset, United Kingdom; †Private Practice, Metz, France; ‡Riverbanks Clinic, Bedfordshire, United Kingdom; §Clínica Moisés Amselem, Madrid, Spain; ‖Clínica Dermatológica Internacional Skinlogic, Madrid, Spain; ¶Galderma R&D, Sophia Antipolis, France; #Freelance office, Epinay-Sous-Sénart, France; **AESTHETICS, Bordeaux, France.
authors.forename: Beatriz
authors.initials: B
authors.lastname: Molina
authors.forename: Michel
authors.initials: M
authors.lastname: David
authors.forename: Ravi
authors.initials: R
authors.lastname: Jain
authors.forename: Moisés
authors.initials: M
authors.lastname: Amselem
authors.forename: Ricardo
authors.initials: R
authors.lastname: Ruiz-Rodriguez
authors.forename: May Y
authors.initials: MY
authors.lastname: Ma
authors.forename: Nabil
authors.initials: N
authors.lastname: Kerrouche
authors.forename: Sotirios P
authors.initials: SP
authors.lastname: Georgantopoulos
authors.forename: Thierry
authors.initials: T
authors.lastname: Radeau
authors.forename: Dominique
authors.initials: D
authors.lastname: Boineau
mesh_terms: D000293:Adolescent; D000328:Adult; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D003357:Cosmetic Techniques; D004338:Drug Combinations; D005145:Face; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage*; D007267:Injections; D008297:Male; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000008:administration & dosage; D017060:Patient Satisfaction; D011788:Quality of Life; D012060:Rejuvenation; D015595:Skin Aging / Q000187:drug effects*; D016896:Treatment Outcome; D055675:Viscosupplements / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D004338:Drug Combinations; D009465:Neuromuscular Agents; D055675:Viscosupplements; D006820:Hyaluronic Acid; D019274:Botulinum Toxins, Type A